首页 > 最新文献

International Journal of Rheumatic Diseases最新文献

英文 中文
BPIFA1 alleviates allergic rhinitis by regulating the NF-κB signaling pathway and Treg/Th17 balance BPIFA1通过调节NF-κB信号通路和Treg/Th17平衡缓解过敏性鼻炎。
IF 2.4 4区 医学 Q2 RHEUMATOLOGY Pub Date : 2024-10-25 DOI: 10.1111/1756-185X.15372
Ying Yang, Shidong Li, Hongyan Xu

Aim

Allergic rhinitis (AR) is an allergic condition characterized by inflammation of the nasal mucosa. Bacterial permeability-increasing family member A1 (BPIFA1) exhibits anti-inflammatory properties; however, its impact on AR remains unclear. Aim of this study is to investigate the expression and function of BPIFA1 in AR and its influence on inflammation and immune regulation in a mouse model of AR induced by ovalbumin (OVA).

Methods

The expression of BPIFA1 was analyzed using quantitative real-time PCR (qRT-PCR) and immunohistochemistry (IHC). Morphological assessments of nasal mucosal tissues were conducted. Levels of inflammatory mediators in nasal lavage fluid (NALF) and serum were quantified using enzyme-linked immunosorbent assay (ELISA) kits. Protein expressions of BPIFA1, phosphorylated and total p65 (p-p65/p65), and IκBα were evaluated through Western blot analysis. The total cell counts, including epithelial cells, eosinophils, and lymphocytes in NALF, were determined using a hemocytometer. A mouse model of AR was established by OVA management.

Results

BPIFA1 expression was found to be reduced in the nasal mucosa tissues of patients with AR, suggesting a potential role in the disease's progression. We successfully developed a mouse model of AR, where BPIFA1 was similarly downregulated, indicating its possible involvement in modulating the NF-κB signaling pathway. Overexpression of BPIFA1 in this model attenuated inflammation and allergic responses by inhibiting the NF-κB pathway. Additionally, overexpression of BPIFA1 promoted the differentiation of regulatory T cells (Treg) and inhibited the differentiation of T helper 17 cells (Th17) in the NALF of AR mice, further demonstrating its regulatory impact on immune responses. The study confirmed that BPIFA1 upregulation reduced the levels of inflammatory cytokines TNF-α and IL-6, decreased infiltration of inflammatory cells, and modulated antigen-specific immunoglobulin levels and histamine in serum.

Conclusion

BPIFA1 mitigated both inflammatory and allergic responses in AR mice induced by OVA through the modulation of the NF-κB signaling pathway and the balance between regulatory T cells (Treg) and T helper 17 cells (Th17). These findings suggest that BPIFA1 could serve as a novel biomarker and therapeutic target for AR, offering potential for the development of targeted treatments to improve patient outcomes.

目的:过敏性鼻炎(AR)是一种以鼻粘膜炎症为特征的过敏性疾病。细菌渗透性增加家族成员 A1(BPIFA1)具有抗炎特性,但其对 AR 的影响仍不清楚。本研究旨在研究 BPIFA1 在卵清蛋白(OVA)诱导的 AR 小鼠模型中的表达和功能及其对炎症和免疫调节的影响:方法:采用定量实时PCR(qRT-PCR)和免疫组织化学(IHC)分析BPIFA1的表达。对鼻粘膜组织进行形态学评估。使用酶联免疫吸附试验(ELISA)试剂盒对鼻腔灌洗液(NALF)和血清中的炎症介质水平进行了定量分析。通过 Western 印迹分析评估了 BPIFA1、磷酸化 p65 和总 p65(p-p65/p65)以及 IκBα 的蛋白表达。使用血细胞计数器测定了细胞总数,包括 NALF 中的上皮细胞、嗜酸性粒细胞和淋巴细胞。通过OVA管理建立了AR小鼠模型:结果:发现BPIFA1在AR患者的鼻粘膜组织中表达减少,这表明BPIFA1在疾病的发展过程中起着潜在的作用。我们成功建立了一个 AR 小鼠模型,在该模型中,BPIFA1 也同样被下调,这表明它可能参与了 NF-κB 信号通路的调节。在该模型中,过表达 BPIFA1 可抑制 NF-κB 通路,从而减轻炎症和过敏反应。此外,在AR小鼠的NALF中,过表达BPIFA1可促进调节性T细胞(Treg)的分化,抑制T辅助17细胞(Th17)的分化,进一步证明了它对免疫反应的调节作用。研究证实,BPIFA1 的上调降低了炎性细胞因子 TNF-α 和 IL-6 的水平,减少了炎性细胞的浸润,并调节了血清中抗原特异性免疫球蛋白和组胺的水平:结论:BPIFA1通过调节NF-κB信号通路以及调节性T细胞(Treg)和T辅助17细胞(Th17)之间的平衡,减轻了OVA诱导的AR小鼠的炎症和过敏反应。这些研究结果表明,BPIFA1可作为AR的新型生物标记物和治疗靶点,为开发靶向治疗以改善患者预后提供了潜力。
{"title":"BPIFA1 alleviates allergic rhinitis by regulating the NF-κB signaling pathway and Treg/Th17 balance","authors":"Ying Yang,&nbsp;Shidong Li,&nbsp;Hongyan Xu","doi":"10.1111/1756-185X.15372","DOIUrl":"10.1111/1756-185X.15372","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>Allergic rhinitis (AR) is an allergic condition characterized by inflammation of the nasal mucosa. Bacterial permeability-increasing family member A1 (BPIFA1) exhibits anti-inflammatory properties; however, its impact on AR remains unclear. Aim of this study is to investigate the expression and function of BPIFA1 in AR and its influence on inflammation and immune regulation in a mouse model of AR induced by ovalbumin (OVA).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The expression of BPIFA1 was analyzed using quantitative real-time PCR (qRT-PCR) and immunohistochemistry (IHC). Morphological assessments of nasal mucosal tissues were conducted. Levels of inflammatory mediators in nasal lavage fluid (NALF) and serum were quantified using enzyme-linked immunosorbent assay (ELISA) kits. Protein expressions of BPIFA1, phosphorylated and total p65 (p-p65/p65), and IκBα were evaluated through Western blot analysis. The total cell counts, including epithelial cells, eosinophils, and lymphocytes in NALF, were determined using a hemocytometer. A mouse model of AR was established by OVA management.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>BPIFA1 expression was found to be reduced in the nasal mucosa tissues of patients with AR, suggesting a potential role in the disease's progression. We successfully developed a mouse model of AR, where BPIFA1 was similarly downregulated, indicating its possible involvement in modulating the NF-κB signaling pathway. Overexpression of BPIFA1 in this model attenuated inflammation and allergic responses by inhibiting the NF-κB pathway. Additionally, overexpression of BPIFA1 promoted the differentiation of regulatory T cells (Treg) and inhibited the differentiation of T helper 17 cells (Th17) in the NALF of AR mice, further demonstrating its regulatory impact on immune responses. The study confirmed that BPIFA1 upregulation reduced the levels of inflammatory cytokines TNF-α and IL-6, decreased infiltration of inflammatory cells, and modulated antigen-specific immunoglobulin levels and histamine in serum.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>BPIFA1 mitigated both inflammatory and allergic responses in AR mice induced by OVA through the modulation of the NF-κB signaling pathway and the balance between regulatory T cells (Treg) and T helper 17 cells (Th17). These findings suggest that BPIFA1 could serve as a novel biomarker and therapeutic target for AR, offering potential for the development of targeted treatments to improve patient outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"27 10","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142500521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of non-coding RNAs in fibroblast-like synoviocytes in rheumatoid arthritis 非编码 RNA 在类风湿性关节炎成纤维细胞样滑膜细胞中的作用。
IF 2.4 4区 医学 Q2 RHEUMATOLOGY Pub Date : 2024-10-23 DOI: 10.1111/1756-185X.15376
Yongquan Zheng, Xiaoyu Cai, Fujia Ren, Yao Yao

Rheumatoid arthritis (RA) is an inflammatory autoimmune disease characterized by synovial hyperplasia, and fibroblast-like synoviocytes (FLSs) constitute the majority of cells in the synovial tissue, playing a crucial role in the onset of RA. Dysregulation of FLSs function is a critical strategy in treating joint damage associated with RA. Non-coding RNAs, a class of RNA molecules that do not encode proteins, participate in the development of various diseases. This article aims to review the progress in the study of long non-coding RNAs, microRNAs, and circular RNAs in FLSs. Non-coding RNAs are involved in the pathogenesis of RA, directly or indirectly regulating FLSs' proliferation, migration, invasion, apoptosis, and inflammatory responses. Furthermore, non-coding RNAs also influence DNA methylation and osteogenic differentiation in FLSs. Therefore, non-coding RNAs hold promise as biomarkers for diagnosing RA. Targeting non-coding RNAs in FLSs locally represents a potential strategy for future therapies in RA.

类风湿性关节炎(RA)是一种以滑膜增生为特征的炎症性自身免疫性疾病,成纤维细胞样滑膜细胞(FLSs)是滑膜组织中的主要细胞,在 RA 的发病中起着至关重要的作用。调控FLSs的功能是治疗与RA相关的关节损伤的关键策略。非编码 RNA 是一类不编码蛋白质的 RNA 分子,它参与了多种疾病的发展。本文旨在回顾长非编码 RNA、microRNA 和环状 RNA 在 FLSs 中的研究进展。非编码 RNA 参与了 RA 的发病机制,直接或间接调控 FLSs 的增殖、迁移、侵袭、凋亡和炎症反应。此外,非编码 RNA 还会影响 FLSs 的 DNA 甲基化和成骨分化。因此,非编码 RNA 有希望成为诊断 RA 的生物标记物。局部靶向 FLSs 中的非编码 RNA 是未来治疗 RA 的一种潜在策略。
{"title":"The role of non-coding RNAs in fibroblast-like synoviocytes in rheumatoid arthritis","authors":"Yongquan Zheng,&nbsp;Xiaoyu Cai,&nbsp;Fujia Ren,&nbsp;Yao Yao","doi":"10.1111/1756-185X.15376","DOIUrl":"10.1111/1756-185X.15376","url":null,"abstract":"<p>Rheumatoid arthritis (RA) is an inflammatory autoimmune disease characterized by synovial hyperplasia, and fibroblast-like synoviocytes (FLSs) constitute the majority of cells in the synovial tissue, playing a crucial role in the onset of RA. Dysregulation of FLSs function is a critical strategy in treating joint damage associated with RA. Non-coding RNAs, a class of RNA molecules that do not encode proteins, participate in the development of various diseases. This article aims to review the progress in the study of long non-coding RNAs, microRNAs, and circular RNAs in FLSs. Non-coding RNAs are involved in the pathogenesis of RA, directly or indirectly regulating FLSs' proliferation, migration, invasion, apoptosis, and inflammatory responses. Furthermore, non-coding RNAs also influence DNA methylation and osteogenic differentiation in FLSs. Therefore, non-coding RNAs hold promise as biomarkers for diagnosing RA. Targeting non-coding RNAs in FLSs locally represents a potential strategy for future therapies in RA.</p>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"27 10","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142500526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Similarities and differences between interstitial lung disease associated with rheumatoid arthritis and systemic sclerosis—A retrospective cohort study 与类风湿性关节炎和系统性硬化症相关的间质性肺病的异同--一项回顾性队列研究。
IF 2.4 4区 医学 Q2 RHEUMATOLOGY Pub Date : 2024-10-23 DOI: 10.1111/1756-185X.15392
Ana Catarina Duarte, Maria José Santos
{"title":"Similarities and differences between interstitial lung disease associated with rheumatoid arthritis and systemic sclerosis—A retrospective cohort study","authors":"Ana Catarina Duarte,&nbsp;Maria José Santos","doi":"10.1111/1756-185X.15392","DOIUrl":"10.1111/1756-185X.15392","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"27 10","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142500525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Liver fibrosis in inflammatory arthritis patients treated with methotrexate and hydroxychloroquine: A FIB-4 index analysis 接受甲氨蝶呤和羟氯喹治疗的炎症性关节炎患者的肝纤维化:FIB-4指数分析
IF 2.4 4区 医学 Q2 RHEUMATOLOGY Pub Date : 2024-10-23 DOI: 10.1111/1756-185X.15390
Güllü Sandal Uzun, Buğu Bulat, Gizem Ayan, Levent Kılıç, Umut Kalyoncu

Objectives

To evaluate the risk of liver fibrosis and associated factors with the non-invasive fibrosis score-4 (FIB-4) index in patients with inflammatory arthritis using methotrexate (MTX).

Methods

Patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) who were followed up in the rheumatology outpatient clinic, who were on methotrexate only and for whom FIB-4 index was could be calculated at methotrexate initiation and follow-up were included. The FIB-4 index was calculated according to the following formula: age (years) × AST(IU/L)/(platelet count(10 (9)/L) × √ALT(IU/L)). The patients' demographics, comorbidities, other treatments, cumulative MTX dose, and reasons for MTX cessation were assessed. For the multivariate analysis, possible factors associated with intermediate-high risk FIB-4 index at last visit were determined.

Results

A total of 107 patients were enrolled in the study, of whom 82 (76.6%) had RA and 25 (23.4%) had PsA. At the initiation of MTX, 24 (22.4%) patients had intermediate-high risk FIB-4 index. Comorbidities and the rate of ≥3–4 Charlson comorbidity index were more common in patients with intermediate-high risk FIB-4 index. A total of 37 (34.5%) patients had intermediate-high risk FIB-4 index at the last visit after median 3.6 (0.3–22.06) years follow-up. The median cumulative MTX dose was 2550 mg (1050–13.991). Cumulative MTX dose [OR 1.18 (1.01–1.33), p = .03] and diabetes mellitus [OR 4.60 (1.74–12.50), p = .002] were associated factors with intermediate-high risk FIB-4 index. The concomitant use of hydroxychloroquine (HCQ) was found to be a low-risk factor for FIB-4 index [OR 0.28 (0.10–0.78) p = .015].

Conclusion

The FIB-4 index is a non-invasive method that can be used in daily rheumatology practice for the evaluation and follow-up of patients who will use methotrexate. Comorbidities and cumulative MTX dose seem to be related with the risk of liver fibrosis. Concomitant use of HCQ with MTX may reduce the risk of liver fibrosis.

目的评估使用甲氨蝶呤(MTX)的炎症性关节炎患者肝纤维化的风险以及与非侵入性肝纤维化评分-4(FIB-4)指数相关的因素:方法:纳入在风湿病门诊随访的类风湿性关节炎(RA)和银屑病关节炎(PsA)患者,这些患者仅使用甲氨蝶呤,且在开始使用甲氨蝶呤和随访时可计算FIB-4指数。FIB-4 指数的计算公式如下:年龄(岁)×AST(IU/L)/(血小板计数(10(9)/L)×√ALT(IU/L))。对患者的人口统计学特征、合并症、其他治疗、MTX累积剂量以及停用MTX的原因进行了评估。在多变量分析中,确定了最后一次就诊时与中高风险 FIB-4 指数相关的可能因素:共有107名患者参与研究,其中82人(76.6%)患有RA,25人(23.4%)患有PsA。在开始使用MTX时,24名(22.4%)患者的FIB-4指数为中高风险。合并症和 Charlson 合并症指数≥3-4 的患者在 FIB-4 指数为中高风险的患者中更为常见。在中位随访3.6(0.3-22.06)年后的最后一次随访中,共有37名(34.5%)患者的FIB-4指数为中高风险。MTX累积剂量中位数为2550毫克(1050-13.991)。MTX累积剂量[OR 1.18 (1.01-1.33),p = .03]和糖尿病[OR 4.60 (1.74-12.50),p = .002]是中高风险FIB-4指数的相关因素。同时使用羟氯喹(HCQ)是FIB-4指数的低风险因素[OR 0.28 (0.10-0.78) p = .015]:结论:FIB-4指数是一种非侵入性方法,可用于日常风湿病学实践中对将使用甲氨蝶呤的患者进行评估和随访。合并症和MTX累积剂量似乎与肝纤维化的风险有关。在使用MTX的同时使用HCQ可降低肝纤维化的风险。
{"title":"Liver fibrosis in inflammatory arthritis patients treated with methotrexate and hydroxychloroquine: A FIB-4 index analysis","authors":"Güllü Sandal Uzun,&nbsp;Buğu Bulat,&nbsp;Gizem Ayan,&nbsp;Levent Kılıç,&nbsp;Umut Kalyoncu","doi":"10.1111/1756-185X.15390","DOIUrl":"10.1111/1756-185X.15390","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To evaluate the risk of liver fibrosis and associated factors with the non-invasive fibrosis score-4 (FIB-4) index in patients with inflammatory arthritis using methotrexate (MTX).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) who were followed up in the rheumatology outpatient clinic, who were on methotrexate only and for whom FIB-4 index was could be calculated at methotrexate initiation and follow-up were included. The FIB-4 index was calculated according to the following formula: age (years) × AST(IU/L)/(platelet count(10 (9)/L) × √ALT(IU/L)). The patients' demographics, comorbidities, other treatments, cumulative MTX dose, and reasons for MTX cessation were assessed. For the multivariate analysis, possible factors associated with intermediate-high risk FIB-4 index at last visit were determined.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 107 patients were enrolled in the study, of whom 82 (76.6%) had RA and 25 (23.4%) had PsA. At the initiation of MTX, 24 (22.4%) patients had intermediate-high risk FIB-4 index. Comorbidities and the rate of ≥3–4 Charlson comorbidity index were more common in patients with intermediate-high risk FIB-4 index. A total of 37 (34.5%) patients had intermediate-high risk FIB-4 index at the last visit after median 3.6 (0.3–22.06) years follow-up. The median cumulative MTX dose was 2550 mg (1050–13.991). Cumulative MTX dose [OR 1.18 (1.01–1.33), <i>p</i> = .03] and diabetes mellitus [OR 4.60 (1.74–12.50), <i>p</i> = .002] were associated factors with intermediate-high risk FIB-4 index. The concomitant use of hydroxychloroquine (HCQ) was found to be a low-risk factor for FIB-4 index [OR 0.28 (0.10–0.78) <i>p</i> = .015].</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The FIB-4 index is a non-invasive method that can be used in daily rheumatology practice for the evaluation and follow-up of patients who will use methotrexate. Comorbidities and cumulative MTX dose seem to be related with the risk of liver fibrosis. Concomitant use of HCQ with MTX may reduce the risk of liver fibrosis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"27 10","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185X.15390","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142500523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
TNF-α inhibitor-induced erythema nodosum: Case report and literature review TNF-α 抑制剂诱发的结节性红斑:病例报告和文献综述。
IF 2.4 4区 医学 Q2 RHEUMATOLOGY Pub Date : 2024-10-23 DOI: 10.1111/1756-185X.15383
Zeinab Saleh, Zenus Saleh, Wendy Marder
{"title":"TNF-α inhibitor-induced erythema nodosum: Case report and literature review","authors":"Zeinab Saleh,&nbsp;Zenus Saleh,&nbsp;Wendy Marder","doi":"10.1111/1756-185X.15383","DOIUrl":"10.1111/1756-185X.15383","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"27 10","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142500527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to “An audit of the initial 12 months of a multi-disciplinary pulmonary hypertension clinic in South Western Sydney (Campbelltown Hospital)” 对 "悉尼西南部多学科肺动脉高压诊所(坎贝尔镇医院)最初 12 个月的审计 "的更正
IF 2.4 4区 医学 Q2 RHEUMATOLOGY Pub Date : 2024-10-23 DOI: 10.1111/1756-185X.15386

Goon K, Metti F, Kamalaraj N. An audit of the initial 12 months of a multi-disciplinary pulmonary hypertension clinic in South Western Sydney (Campbelltown Hospital). Int J of Rheum Dis. 2024; 27:S2 e15172, 46. https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185X.15172

The second and third authors were omitted from the above abstract.

The correct authors and affiliations are as follows:

Kara Goon1; Fedil Metti2; Narainraj Kamalaraj1, 3

1Department of Rheumatology, Campbelltown Hospital, Campbelltown, Australia

2Department of Thoracic Medicine, Campbelltown Hospital, Campbelltown, Australia

3Western Sydney University, Campbelltown, Australia

The online article has been corrected.

We apologize for this error.

Goon K、Metti F、Kamalaraj N. 对悉尼西南部(坎贝尔镇医院)多学科肺动脉高压诊所最初 12 个月的审计。Int J of Rheum Dis.2024; 27:S2 e15172, 46. https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185X.15172The 第二和第三作者在上述摘要中被省略。正确的作者和单位如下:Kara Goon1; Fedil Metti2; Narainraj Kamalaraj1, 31澳大利亚坎贝尔镇坎贝尔镇医院风湿病科2澳大利亚坎贝尔镇坎贝尔镇医院胸腔内科3澳大利亚坎贝尔镇西悉尼大学在线文章已更正。我们对这一错误表示歉意。
{"title":"Correction to “An audit of the initial 12 months of a multi-disciplinary pulmonary hypertension clinic in South Western Sydney (Campbelltown Hospital)”","authors":"","doi":"10.1111/1756-185X.15386","DOIUrl":"https://doi.org/10.1111/1756-185X.15386","url":null,"abstract":"<p>Goon K, Metti F, Kamalaraj N. An audit of the initial 12 months of a multi-disciplinary pulmonary hypertension clinic in South Western Sydney (Campbelltown Hospital). <i>Int J of Rheum Dis</i>. 2024; 27:S2 e15172, 46. https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185X.15172</p><p>The second and third authors were omitted from the above abstract.</p><p>The correct authors and affiliations are as follows:</p><p><span>Kara Goon</span><sup>1</sup>; Fedil Metti<sup>2</sup>; Narainraj Kamalaraj<sup>1, 3</sup></p><p><sup>1</sup>Department of Rheumatology, Campbelltown Hospital, Campbelltown, Australia</p><p><sup>2</sup>Department of Thoracic Medicine, Campbelltown Hospital, Campbelltown, Australia</p><p><sup>3</sup>Western Sydney University, Campbelltown, Australia</p><p>The online article has been corrected.</p><p>We apologize for this error.</p>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"27 10","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185X.15386","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142525029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Olokizumab effect on chronic pain in rheumatoid arthritis: Results of the PROLOGUE observational study Olokizumab 对类风湿性关节炎慢性疼痛的影响:PROLOGUE 观察性研究的结果。
IF 2.4 4区 医学 Q2 RHEUMATOLOGY Pub Date : 2024-10-23 DOI: 10.1111/1756-185X.15320
А. Е. Karateev, Е. Y. Polishchuk, Е. S. Filatova, V. N. Amirdzhanova, V. N. Khlaboshina, А. М. Lila, A. A. Baranov, N. A. Lapkina, G. A. Togizbayev

Aim

Evaluate the efficacy and safety ® (olokizumab) in patients with rheumatoid arthritis (RA) in real-world clinical practice, with a targeted assessment of patient report outcomes (PRO) and central sensitization.

Methods

An open-label observational non-interventional study was conducted, enrolling 183 patients with moderate and severe RA activity. All patients received OKZ 64 mg SC as injections every 4 weeks (Q4W) with methotrexate. The patients' follow-up period was 24 weeks or less. RA activity (DAS28-CRP), pain severity (NRS), patient global assessment (PGA, NRS), functional impairment (NRS), fatigue (FACIT-F), central sensitization (central sensitization inventory, CSI), and symptoms of neuropathic pain (PainDETECT) were evaluated.

Results

The study cohort was comprised of 144 patients. And 39 patients were lost to follow-up, refused OKZ treatment, or were not dosed with OKZ for administrative reasons. In 6 months, DAS28-CRP decreased to 3.3 ± 0.9 (p < .001) and statistically significant reductions in pain intensity, PGA, functional impairment, and fatigue were achieved. Pain intensity decreased as early as 2 days after the first OKZ administration (p < .05). The number of patients with CSI >40 in 24 weeks decreased from 71.0% to 21.0% (p < .001), with PainDETECT >18 – from 21.5% to 13.2%. NSAIDs use decreased from 70.8% to 33.8% (р < .001), steroids – from 54.2% to 32.6%. AEs were reported in 14.2% patients, serious events were observed in three patients.

Conclusion

OKZ is effective in reducing RA activity and controlling chronic pain related to dysfunction of the nociceptive system.

目的:评估®(olokizumab)在实际临床实践中对类风湿关节炎(RA)患者的疗效和安全性,有针对性地评估患者报告结果(PRO)和中枢敏感性:我们开展了一项开放标签观察性非干预研究,共招募了 183 名中度和重度类风湿关节炎活动期患者。所有患者每4周(Q4W)接受一次OKZ 64毫克皮下注射,同时服用甲氨蝶呤。患者的随访期为 24 周或更短。研究人员对患者的RA活动度(DAS28-CRP)、疼痛严重程度(NRS)、患者整体评估(PGA、NRS)、功能障碍(NRS)、疲劳(FACIT-F)、中枢敏化(中枢敏化清单,CSI)和神经性疼痛症状(PainDETECT)进行了评估:研究队列由 144 名患者组成。结果:研究队列由 144 名患者组成,其中 39 名患者失去了随访机会、拒绝接受 OKZ 治疗或因管理原因未使用 OKZ。6个月后,DAS28-CRP降至3.3 ± 0.9(P 40);24周后,DAS28-CRP从71.0%降至21.0%(P 18 - 从21.5%降至13.2%)。非甾体抗炎药的使用率从 70.8% 降至 33.8% (р 结论:OKZ能够有效减少RA活动,控制与痛觉系统功能障碍有关的慢性疼痛。
{"title":"Olokizumab effect on chronic pain in rheumatoid arthritis: Results of the PROLOGUE observational study","authors":"А. Е. Karateev,&nbsp;Е. Y. Polishchuk,&nbsp;Е. S. Filatova,&nbsp;V. N. Amirdzhanova,&nbsp;V. N. Khlaboshina,&nbsp;А. М. Lila,&nbsp;A. A. Baranov,&nbsp;N. A. Lapkina,&nbsp;G. A. Togizbayev","doi":"10.1111/1756-185X.15320","DOIUrl":"10.1111/1756-185X.15320","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>Evaluate the efficacy and safety ® (olokizumab) in patients with rheumatoid arthritis (RA) in real-world clinical practice, with a targeted assessment of patient report outcomes (PRO) and central sensitization.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>An open-label observational non-interventional study was conducted, enrolling 183 patients with moderate and severe RA activity. All patients received OKZ 64 mg SC as injections every 4 weeks (Q4W) with methotrexate. The patients' follow-up period was 24 weeks or less. RA activity (DAS28-CRP), pain severity (NRS), patient global assessment (PGA, NRS), functional impairment (NRS), fatigue (FACIT-F), central sensitization (central sensitization inventory, CSI), and symptoms of neuropathic pain (PainDETECT) were evaluated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The study cohort was comprised of 144 patients. And 39 patients were lost to follow-up, refused OKZ treatment, or were not dosed with OKZ for administrative reasons. In 6 months, DAS28-CRP decreased to 3.3 ± 0.9 (<i>p</i> &lt; .001) and statistically significant reductions in pain intensity, PGA, functional impairment, and fatigue were achieved. Pain intensity decreased as early as 2 days after the first OKZ administration (<i>p</i> &lt; .05). The number of patients with CSI &gt;40 in 24 weeks decreased from 71.0% to 21.0% (<i>p</i> &lt; .001), with PainDETECT &gt;18 – from 21.5% to 13.2%. NSAIDs use decreased from 70.8% to 33.8% (<i>р</i> &lt; .001), steroids – from 54.2% to 32.6%. AEs were reported in 14.2% patients, serious events were observed in three patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>OKZ is effective in reducing RA activity and controlling chronic pain related to dysfunction of the nociceptive system.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"27 10","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185X.15320","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142500524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epicardial fat thickness in rheumatoid arthritis: Insights from echocardiographic analysis and autoimmune correlations 类风湿性关节炎的心外膜脂肪厚度:超声心动图分析和自身免疫相关性的启示
IF 2.4 4区 医学 Q2 RHEUMATOLOGY Pub Date : 2024-10-23 DOI: 10.1111/1756-185X.15394
Nuran Öz
{"title":"Epicardial fat thickness in rheumatoid arthritis: Insights from echocardiographic analysis and autoimmune correlations","authors":"Nuran Öz","doi":"10.1111/1756-185X.15394","DOIUrl":"10.1111/1756-185X.15394","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"27 10","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142500522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An insight into neonatal hemophagocytic lymphohistiocytosis from a clinician's perspective 从临床医生的角度看新生儿嗜血细胞淋巴组织细胞增多症
IF 2.4 4区 医学 Q2 RHEUMATOLOGY Pub Date : 2024-10-21 DOI: 10.1111/1756-185X.15393
Aritra Kapat
{"title":"An insight into neonatal hemophagocytic lymphohistiocytosis from a clinician's perspective","authors":"Aritra Kapat","doi":"10.1111/1756-185X.15393","DOIUrl":"https://doi.org/10.1111/1756-185X.15393","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"27 10","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142451792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A young female with rapid progression of erythroderma and palmoplantar keratoderma 一名年轻女性,红斑狼疮和掌跖角化症进展迅速
IF 2.4 4区 医学 Q2 RHEUMATOLOGY Pub Date : 2024-10-21 DOI: 10.1111/1756-185X.15384
Ju-Shao Yen, Yi-Teng Hung
{"title":"A young female with rapid progression of erythroderma and palmoplantar keratoderma","authors":"Ju-Shao Yen,&nbsp;Yi-Teng Hung","doi":"10.1111/1756-185X.15384","DOIUrl":"https://doi.org/10.1111/1756-185X.15384","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"27 10","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142451791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
International Journal of Rheumatic Diseases
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1